Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Virginia Heart

Neither a doctor nor a teaching hospital

Research payments

$5,626,235

259 payments

Through program year 2025, Virginia Heart is reported as receiving $5,626,235 in research payments, across 259 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,176,321 19
2024 Research $989,809 16
2023 Research $572,174 16
2022 Research $766,371 11
2021 Research $615,157 135
2020 Research $640,650 29
2019 Research $865,753 33

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $3,483,153 37 payments
  2. Amgen Inc. $1,044,580 32 payments
  3. AstraZeneca Pharmaceuticals LP $750,401 18 payments
  4. Regeneron Pharmaceuticals, Inc. $271,101 27 payments
  5. Merck Sharp & Dohme Corporation $49,780 8 payments
  6. Novo Nordisk AS $13,917 128 payments
  7. Inspire Medical Systems, Inc. $7,502 6 payments
  8. Janssen Research & Development, LLC $5,802 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $2,052,432 6 payments
  2. FOURIER OLE (Ph 4) $642,479 8 payments
  3. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $609,426 7 payments
  4. An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) $514,189 8 payments
  5. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $260,369 7 payments
  6. 20160250-FOURIER OLE (Ph 4) $215,940 2 payments
  7. A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE) $145,920 3 payments
  8. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Iiib Study Evaluating the Effect of Inclisiran on Atherosclerotic Plaque Progression Assessed By Coronary Computed Tomography Angiography (Ccta) in Participants With A Diag $128,459 2 payments
  9. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk $128,041 10 payments
  10. OCEANa-Outcomes P3 CV $95,906 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record